Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 1 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Results 1 - 20 of 25 : 1 2 Next »

Recs

0
Member Avatar EnigmaDude (98.04) Submitted: 3/5/2014 1:10:17 PM : Outperform Start Price: $2.40 PPHM Score: -28.75

breakout in progress ...

Recs

0
Member Avatar AndrewGreenBull (99.31) Submitted: 2/21/2014 1:18:36 PM : Outperform Start Price: $1.75 PPHM Score: -4.48

Take a look at PPHM's robust pipeline, and you will know that current market cap $300 millions has a lot more upside potential. Bavituximab can be next blockbuster drug.

For the near term, the candle stick chart send out a strong rising signal. I won't be surprise if PPHM goes up over $3 with a sudden jump.

Recs

0
Member Avatar biznessdoc (57.26) Submitted: 1/22/2014 2:02:49 PM : Outperform Start Price: $1.80 PPHM Score: -7.16

Developing immune response to cancer that has been impressive when linked with other medications.

Recs

0
Member Avatar lorenzo404 (36.63) Submitted: 1/7/2014 8:11:26 PM : Outperform Start Price: $1.60 PPHM Score: +3.82

rad

Recs

0
Member Avatar reidroberson (< 20) Submitted: 11/14/2013 9:37:38 PM : Outperform Start Price: $1.30 PPHM Score: +25.86

Peregrine is an interesting and dynamic company with consistent success.

Recs

0
Member Avatar JPlace09 (< 20) Submitted: 11/7/2013 9:54:36 PM : Outperform Start Price: $1.23 PPHM Score: +30.44

Despite the poorly run early stage trials, I think they might have a winner in Bavituximab. We'll see.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:48:22 PM : Underperform Start Price: $1.38 PPHM Score: -8.80

Short. Pharma. Consistent operating losses. Constantly selling stock.

Recs

0
Member Avatar Tara55 (< 20) Submitted: 6/7/2013 6:17:35 AM : Outperform Start Price: $1.67 PPHM Score: -12.69

They are undervalued at under $2 with a target of $7 IF they get a product to market Risk 6/7 (with 10= V/LOW risk)

Recs

1
Member Avatar JohnT106 (53.39) Submitted: 3/8/2013 8:59:03 AM : Outperform Start Price: $1.41 PPHM Score: -0.25

Peregrine is advancing two novel cancer drug candidates that, combined with its hybrid business model, present attractive risk-reward opportunities in our view. Lead candidate bavituximab (bavi') has recently endured negative news flow, increasing skepticism from investors but creating a potential buying opportunity

Recs

0
Member Avatar Amagi (99.77) Submitted: 3/5/2013 11:19:38 PM : Outperform Start Price: $1.43 PPHM Score: -2.40

speculative tip from a random person

Recs

0
Member Avatar HoldThatWinner (33.95) Submitted: 2/13/2013 3:27:23 PM : Outperform Start Price: $1.83 PPHM Score: -30.45

I always seem to get crappy prices on this Caps "game". I bought the Bear Raid in Real ife in the $1.60s.
I had a limit order here on the Caps at 1.65 that never executed so I then placed a regular order when it was trading at 1.80 forever and the Caps started me off at 1.83. Whatever. I'll play it from 1.83 on the bear raid in the Caps and from the 1.60s (much better :-) ) in Real Life.

Recs

0
Member Avatar scrubs62074 (88.72) Submitted: 2/13/2013 11:17:30 AM : Outperform Start Price: $2.15 PPHM Score: -43.93

High Volume Breakout on 02/13/13

Recs

0
Member Avatar Pandasdad (< 20) Submitted: 12/8/2012 11:04:24 AM : Outperform Start Price: $1.24 PPHM Score: +4.96

A speculator's dream date. This stock recently suffered a tremendous loss due to the negligent actions of a third party contractor. The speculation that this company's new cancer durg, now in phase III, will be successful still remains strong. The speculation is bolstered by the positive results of the phase II trial that shows their cancer drug helping people live twice as long as competitors drugs. People now buying into this stock at this historically low level are betting that the mixup between placebos and the actual drug in phase II resulted in a lower overall success rate of the drug fighting cancer and that positive phase III testing results will launch the price well beyond the $5.50 level it recently fell from. The investors that got burned holding on to shares near or at the $5.50 level may never come back, but new speculators with cooler heads and looking for a bargain will buy, hold and push this to newer highs.

Recs

0
Member Avatar JorgeAura (< 20) Submitted: 12/6/2012 7:20:16 PM : Underperform Start Price: $1.13 PPHM Score: -18.44

Dead cat bounce. Bad management.

Recs

0
Member Avatar catfam (< 20) Submitted: 10/13/2012 4:46:33 PM : Outperform Start Price: $0.73 PPHM Score: +100.54

approval of products

Recs

0
Member Avatar Smallcappy (< 20) Submitted: 8/14/2012 10:30:24 AM : Underperform Start Price: $2.64 PPHM Score: +68.12

It has been hyped up and due to fall.

Recs

1
Member Avatar TMFBlacknGold (99.04) Submitted: 8/13/2012 1:43:35 PM : Underperform Start Price: $0.54 PPHM Score: -164.94

This is probably the last time I red thumb a company anywhere near $0.50. Although my pick is quickly approaching -400 points - by far my worst pick active or ever - I am sure the company will fall pretty far soon enough. If only I had followed zz's green thumb at the same entry point I could have enjoyed a swing of over 500 pts. $@!%! me

Recs

2
Member Avatar ssanaka (< 20) Submitted: 3/20/2012 1:04:29 PM : Outperform Start Price: $0.56 PPHM Score: +167.39

good product pipeline

Recs

0
Member Avatar KimLanners (< 20) Submitted: 7/13/2011 6:38:29 PM : Outperform Start Price: $2.26 PPHM Score: -66.10

biot

Recs

1
Member Avatar bmk2 (42.29) Submitted: 1/5/2011 4:09:12 PM : Outperform Start Price: $2.48 PPHM Score: -77.68

Big promise for this first in class treatment.....

Results 1 - 20 of 25 : 1 2 Next »

Featured Broker Partners


Advertisement